CRP and metabolic dysfunction-associated steatotic liver disease: Treatment 3 showed a significant decrease in C‐reactive protein (CRP) (6.32–3.39 mg/L) and erythrocyte sedimentation rate (ESR) (38.72–23.86 mm/h), indicating that individuals with NAFLD may benefit from the intervention's potential benefits in lowering inflammation.